Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentation and Q&A at the 34th Annual J. P. Morgan Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius , President and CEO, will present at the upcoming 34 th Annual J. P.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Oppenheimer 26th Annual Healthcare Conference Webcast
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that David Johnston , Executive Vice President and Chief Financial Officer, will present at the
View HTML
Toggle Summary ImmunoGen, Inc. Announces Data Presentations at Upcoming 57th ASH Annual Meeting and Exposition
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentation of new preclinical data with the Company's experimental therapies IMGN529
View HTML